Jubilant Life up over 5% as arm signs contracts in Radiopharma business

The stock was up 7% to Rs 683 on the BSE in intra-day trade

Jubilant Life Sciences has moved higher by 7% to Rs 683 on the BSE after the company announced that its arm signed long term contracts in Radiopharma business.

“The company’s wholly own subsidiary Jubilant Pharma, through one of its units Jubilant DraxImage Inc. Montreal Canada (JDI), has signed long term contracts with distribution networks in the US for supply of products used for diagnostic and therapeutic procedures for thyroid, myocardial perfusion, lung, kidney and bone scans to be supplied by JDI over a period of 39 months effective from January 2017,” Jubilant Life Sciences said in a release.